timothy sykes logo

Stock News

Capstone Therapeutics: Soaring or Sinking?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Capstone Therapeutics: Soaring or Sinking? Thumbnail

Capstone Holding Corp.’s stocks surged as investors reacted positively to the announcement of a strategic partnership with a leading tech innovator, resulting in increased market confidence. On Monday, Capstone Holding Corp.’s stocks have been trading up by 13.8 percent.

Highlights of Current Market Movement

  • Capstone Therapeutics has announced a massive secondary offering with over 1.25 million shares priced at $4.00, placing them into the spotlight and raising questions about market confidence.

Candlestick Chart

Live Update At 11:38:11 EST: On Monday, March 17, 2025 Capstone Holding Corp. stock [NASDAQ: CAPS] is trending up by 13.8%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • The shares, under the management of Joseph Gunnar, have put investors on edge, as the company embarks on a significant financial maneuver.

  • Despite recent market jitters, fans of Capstone are keenly eyeing this move, hoping it will provide needed funds to fuel future developments in the pharma industry.

  • Observers note potential ripple effects on the stock market, leaving many to wonder if this could be a new beginning or just another challenge for the enigmatic firm.

Navigating the Financial Metrics

According to many successful traders, patience is a key attribute in the world of trading. Impulsive decisions can often lead to unfavorable outcomes, and it’s crucial to have a strategy rather than chasing trends without a clear plan. This sentiment is echoed by millionaire penny stock trader and teacher Tim Sykes, who says, “There is always another play around the corner; don’t chase just because you feel FOMO.” Understanding that the market offers endless opportunities helps in maintaining a calm and disciplined approach, ensuring that decisions are made based on logic and analysis rather than emotions.

Understanding Capstone Holding Corp.’s latest earnings and financial reports paints a picture of a company battling to balance its ambitions and realities. A glance at their profitability shows decent ebit and ebitda margins, hovering at 6.5% and 6.9%, respectively. Yet, despite these seemingly promising figures, their pretax profit margin sits at a modest 4.7%, highlighting the uphill battle the company faces to ensure sustained profitability.

The company’s financial strength metrics reveal a total debt-to-equity ratio of 3.52, with long-term debt reaching up to $2.64 million. The firm’s leverage and rapid turnover of receivables hint at aggressive financial strategies, perhaps necessary given the company’s rapid expansion efforts. Yet, the cloud overhanging is the negative return on capital and low return on equity. Some skeptics wonder if a tweaking of strategy is in the cards to ensure positive outcomes in the future.

Moreover, examining Capstone’s latest income statement, a stark reality unfolds. While research and development expenses hit $427,000, investing in innovation and future pipelines, there remains a significant toll on operating income and net income figures. Reported losses near $668,000 post-EBITDA further underscore the challenging financial landscape the company must navigate.

More Breaking News

Despite these hurdles, Capstone’s cash position provides a silver lining. The firm’s cash on hand, after absorbing net cash flow discrepancies, totals $305,000, reflecting its cautious management of immediate financial operations. However, the overall working capital maintains in a negative zone, suggesting further difficulties in balancing short-term assets and liabilities. With these metrics at play, the company’s financial health remains a curious cocktail proving challenging to sip.

Delving into Current Stock Trends

As CAPS stock demonstrates volatile trading patterns, with prices oscillating between $2.5 and $3.19 over recent days, investors are left catching their breath. Notably, on March 17, 2025, the stock’s close at $2.845 hinted at momentum loss, though the intraday flirtations with higher peaks like $3.63 suggest underlying positivity.

Intraday candlestick movements have been particularly dynamic, hinting at both opportunity and risk. Price ranges during early trading hours show a marked willingness to spike, with notable figures touching $2.60 to $2.80—a rollercoaster that encapsulates the stock’s turbulent personality. Those keeping a sharp eye on these trends must navigate with caution, taking advantage of sporadic peaks while hedging against unavoidable troughs.

Beyond candlestick intricacies and day-to-day trading anecdotes, one realizes the market’s expectations. Could it be anticipation of something significant unfolding post-share offering? Or simply an exercise in furious day-trading, seizing moments of peak activity?

Assessing News Impacts

The combined impact of Capstone’s share offering and financial reports paints a vivid narrative crowded with optimism and apprehension. The decision to issue 1.25 million shares implies strategic growth but is also fraught with risks, especially considering share dilution and potential market volatility.

Under the shadow of this offer, investors grapple with the juxtaposition of Capstone’s ambitious plans and the cold facts of its fiscal status. On one hand, there’s allure in new funds and possible innovations; yet, on the flip, there is caution—a worry the issuance may not align seamlessly with shareholder expectations or market realities.

Joseph Gunnar’s sole bookrunning role hints at possible market trust, but for some, it’s a gamble as they eye industry shifts—for good or ill. This chess move aligns with planned developments in pharma, yet it’s not without precedent. The true market storyline unfolds only as the dust of transactions settles and investors sapiens rest assured—or ready for another flurry.

The Journey Forward: A Reckoning?

As Capstone walks its financial tightrope, traders, analysts, and market pundits gather to gaze at unfolding stories, foreseeing fortunes or foibles. With significant financial maneuvers underway and the spotlight skewering each step, can Capstone rise as a pillar of pharma industry innovation, or will this be just another enigmatic journey fraught with market skeptics and unyielding challenges? As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” The outcome is a journey we’re all on, potentially redefining the very limits of pharma resilience.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”